Tenax Therapeutics (Tenax Therapeutics) Cash Flow from Financing : $13.57 Mil (TTM As of Dec. 2023)

View and export this data going back to 1997. Start your Free Trial

What is Tenax Therapeutics Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Dec. 2023, Tenax Therapeutics paid $0.00 Mil more to buy back shares than it received from issuing new shares. It spent $0.17 Mil paying down its debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $0.00 Mil on other financial activities. In all, Tenax Therapeutics spent $0.17 Mil on financial activities for the three months ended in Dec. 2023.

Tenax Therapeutics Cash Flow from Financing Historical Data

The historical data trend for Tenax Therapeutics's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tenax Therapeutics Cash Flow from Financing Chart

Tenax Therapeutics Annual Data

Trend

Apr14

Apr15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash Flow from Financing

Get a 7-Day Free Trial

0.10

10.60

9.74

7.93

13.57

Tenax Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash Flow from Financing	Get a 7-Day Free Trial															-	14.02	-0.10	-0.17	-0.17

Tenax Therapeutics Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Tenax Therapeutics's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

	Cash Flow from Financing		(A: Dec. 2023 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	0	+	0	+	-0.624	+	0	+	0	+	14.193
=	13.57

Tenax Therapeutics's Cash from Financing for the quarter that ended in Dec. 2023 is:

	Cash Flow from Financing		(Q: Dec. 2023 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	0	+	0	+	-0.174	+	0	+	0	+	0
=	-0.17

Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $13.57 Mil.

Tenax Therapeutics (NAS:TENX) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Tenax Therapeutics's issuance of stock for the three months ended in Dec. 2023 was $0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Tenax Therapeutics's repurchase of stock for the three months ended in Dec. 2023 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Tenax Therapeutics's net issuance of debt for the three months ended in Dec. 2023 was $-0.17 Mil. Tenax Therapeutics spent $0.17 Mil paying down its debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Tenax Therapeutics's net issuance of preferred for the three months ended in Dec. 2023 was $0.00 Mil. Tenax Therapeutics paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Tenax Therapeutics's cash flow for dividends for the three months ended in Dec. 2023 was $0.00 Mil. Tenax Therapeutics received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Tenax Therapeutics's other financing for the three months ended in Dec. 2023 was $0.00 Mil. Tenax Therapeutics received $0.00 Mil on other financial activities.

Tenax Therapeutics Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Tenax Therapeutics's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

Tenax Therapeutics (Tenax Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tenax Therapeutics Inc (NAS:TENX) » Definitions » Cash Flow from Financing

Comparable Companies

Traded in Other Exchanges

N/A

Address

101 Glen Lennox Drive, Suite 300, Chapel Hill, NC, USA, 27517

Website

https://www.tenaxthera.com

Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction.

Executives

Robyn Hunter	director	95 SAWYER ROAD, SUITE 110, WALTHAM MA 02453
Eliot M Lurier	officer: Interim CFO	C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Chrisopher Thomas Giordano	director, officer: CEO	C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Armistice Capital, Llc	director	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital Master Fund Ltd.	director	C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd	director	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
June Sherie Almenoff	director	C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY 10019
Michael H. Davidson	director	OMTHERA PHARMACEUTICALS, INC., 707 STATE ROAD, PRINCETON NJ 08540
Declan Doogan	director	C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
Stuart Rich	officer: Chief Medical Officer	C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Illya Keith Maher	director	C/O ARMISTICE CAPITAL, 510 MADISON AVE., 7TH FLOOR, NEW YORK NY 10022
Ronald R Blanck	director	2001 WALNUT HILL LANE, IRVING TX 75038
Gerald T Proehl	director
James P. Mitchum	director	C/O NEPHROGENEX, INC., 79 T.W. ALEXANDER DRIVE, RESEARCH TRIANGLE PARK NC 27709
John P Kelley	officer: Chief Executive Officer	C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502